Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OBIO vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–3 Matrix Metrics)

OBIO Overall Winner 6-Pillar Tally: OBIO 3 – 2 LYRA (1 Tie) Matrix Metrics: OBIO 5 – 3 LYRA

As of Nov 17, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). OBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $7.02 (N/M Forward P/E, -195.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. OBIO 42.9/100 HOLD), OBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -25032.0% operating margin) and revenue trajectory (-89.4% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs LYRA
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 80% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 68
RSI-14: 68.1 · SMA20: $5.99 · SMA50: $5.94
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 LYRA)

Columns: Metric · OBIO · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.6x 3.9x
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $600,000
Market Cap $570.6M $2.3M
3. Profitability & Quality OBIO
Gross Margin 99.6% N/A
Operating Margin -195.4% -25032.0%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -404.5%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$64M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 70.8% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (5) vs LYRA (3)
Institutional Metric OBIO LYRA Criterion Row Edge
Market Capitalization
Scale
$570.6M $2.3M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-89.4% -87.2% Higher Growth LYRA
Operating Margin (TTM)
Profitability
-195.4% -25032.0% Higher Margin OBIO
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin LYRA
Return on Equity (ROE)
Capital Efficiency
-182.3% -404.5% Higher ROE OBIO
52-Week Range Position
Momentum
89% ($3–$7) 1% ($0–$38) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.15β · 80% Vol 0.33β · 248% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
$31M $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.6x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +81.61 pp
OBIO: +19.11% · LYRA: -62.5%
3M Horizon OBIO +87.18 pp
OBIO: -0.44% · LYRA: -87.62%
6M Horizon OBIO +102.62 pp
OBIO: +15.48% · LYRA: -87.14%
1Y Horizon OBIO +102.62 pp
OBIO: +15.48% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue LYRA Revenue OBIO Op. Margin LYRA Op. Margin Margin Leader
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 $0M $0M -924.3% -4131.0% OBIO
FY2023 $0M $0M -1866.2% -4308.1% OBIO
FY2024 $0M $0M -2437.5% -6280.8% OBIO
FY2025 $30M $0M -154.7% -7794.5% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). OBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $7.02 (N/M Forward P/E, -195.4% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. OBIO 42.9/100 HOLD), OBIO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -25032.0% operating margin) and revenue trajectory (-89.4% vs. -87.2% YoY). Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 5-period historical trajectory (FY2021 to FY2025), OBIO cumulative revenue shifted N/A while LYRA shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.